Nivolumab

纳武利尤单抗

Report date: 2026/05/23 20:00:57
First In Class

Base Information

Drug NameNivolumab
Drug Alias NameNivolumab BMS纳武单抗尼沃鲁单抗nivolumabumnabuliumab +[15] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionProgrammed cell death protein 1 inhibitors
TargetsProgrammed cell death protein 1
Therapy Area/IndicationsUveal melanomaCoronavirus Disease 2019 (COVID-19)Blastic Plasmacytoid Dendritic Cell Neoplasm +[214] 
Global Approved IndicationsCarcinoma, Non-Small-Cell LungMelanoma
Approved Indications in ChinaCarcinoma, Non-Small-Cell Lung
Original Approved Country/TerritoryJapan
Original Approved Date2014/07/04
Country/TerritoryCzechiaBelgiumCanada +[50] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesOno Pharmaceutical Co LtdMedarex Inc
China Registration ClassN/A

Develop Information

Active CompaniesUtah State UniversityCelgene International Ii SarlDana-Farber Cancer Institute +[46] 
Inactive CompaniesShenzhen Hank Bioengineering InstituteOno Pharmaceutical KoreaUniversity Medical Center Groningen +[30] 
Active IndicationsUveal melanomaBrain metastasesEsophageal adenocarcinoma +[182] 
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)Blastic Plasmacytoid Dendritic Cell NeoplasmAngioimmunoblastic T-cell Lymphoma +[32] 

Other Information

ATC CodeL01XC17
Related LinksWikipediaDrugBankKEGG